A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis

NCT01382212 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

End-Stage Renal Disease
Secondary Hyperparathyroidism

Interventions

DRUG: paricalcitol

Sponsor

AbbVie (prior sponsor, Abbott)